Kinaxis® Inc. (TSX:KXS), provider of RapidResponse®, the recognized leader in digital supply chain management for concurrent planning, today announced Vertex Pharmaceuticals Incorporated, a global biotechnology company headquartered in Boston, MA, has selected Kinaxis® to improve its end-to-end planning and operations to reduce supply chain risk.
In response to an increasingly complex supply chain planning environment, Vertex, which focuses on discovering and developing medicines for people with serious diseases, needed a new supply chain solution to help build for the future. With challenges like regulatory requirements that vary significantly by market, Vertex was looking for a supply chain management solution that is flexible and granular enough to allow them to plan production, react to rapid change, and deliver its products on time.
Kinaxis offers a robust cloud-based and attribute-based planning solution to help the company closely monitor the complex planning rules and regulations, including FDA requirements, inherent to delivering life-saving medication to patients when they need it. Using Kinaxis and concurrent planning to synchronize their supply chain functions, Vertex will more effectively manage product on a lot-for-lot basis across its entire digital supply chain. Intelligent, customizable product expiry monitoring will alert the Vertex team when action on inventory is required to maximize customer service while ensuring expiry dates are not surpassed to minimize extra cost.
“Biotechnology companies like Vertex have to deal with some of the most complex and life-affecting supply chains, and they recognize Kinaxis’ deep understanding of these unique challenges,” said John Sicard, Chief Executive Officer, Kinaxis. “With the Kinaxis solution, Vertex will be able to better analyze, plan and respond across their entire supply chain in real time. This increased agility and speed mean Vertex will be better equipped to adapt to meet the full variety of changing regulations that it must adhere to today and in the future.”
Certain statements in this release constitute forward-looking statements within the meaning of applicable securities laws. Forward-looking statements include statements as to Kinaxis' growth opportunities and the potential benefits of, and demand for, Kinaxis’ products and services. These statements are subject to certain assumptions, risks and uncertainties, including our view of the relative position of Kinaxis' products and services compared to competitive offerings in the industry. Readers are cautioned not to place undue reliance on such statements. Kinaxis' actual results, performance, achievements and developments may differ materially from the results, performance, achievements or developments expressed or implied by such statements. Risk factors that may cause the actual results, performance, achievements or developments of Kinaxis to differ materially from the results, performance, achievements or developments expressed or implied by such statements can be found in the public documents filed by Kinaxis with Canadian securities regulatory authorities. Kinaxis assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by law.